Medication Utilization and Annual Health Care Costs in Patients With Type 2 Diabetes Mellitus Before and After Bariatric Surgery | Bariatric Surgery | JAMA Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Zimmet  P, Alberti  KG, Shaw  J.  Global and societal implications of the diabetes epidemic.  Nature. 2001;414(6865):782-787. PubMedGoogle ScholarCrossref
2.
Leibson  CL, Williamson  DF, Melton  LJ  III,  et al.  Temporal trends in BMI among adults with diabetes.  Diabetes Care. 2001;24(9):1584-1589. PubMedGoogle ScholarCrossref
3.
Norris  SL, Zhang  X, Avenell  A,  et al.  Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis.  Am J Med. 2004;117(10):762-774. PubMedGoogle ScholarCrossref
4.
Ferchak  CV, Meneghini  LF.  Obesity, bariatric surgery and type 2 diabetes—a systematic review.  Diabetes Metab Res Rev. 2004;20(6):438-445. PubMedGoogle ScholarCrossref
5.
Saaddine  JB, Engelgau  MM, Beckles  GL, Gregg  EW, Thompson  TJ, Narayan  KM.  A diabetes report card for the United States: quality of care in the 1990s.  Ann Intern Med. 2002;136(8):565-574. PubMedGoogle ScholarCrossref
6.
Sjöström  L, Lindroos  AK, Peltonen  M,  et al; Swedish Obese Subjects Study Scientific Group.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.  N Engl J Med. 2004;351(26):2683-2693. PubMedGoogle ScholarCrossref
7.
Adams  TD, Gress  RE, Smith  SC,  et al.  Long-term mortality after gastric bypass surgery.  N Engl J Med. 2007;357(8):753-761. PubMedGoogle ScholarCrossref
8.
Kopp  HP, Kopp  CW, Festa  A,  et al.  Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients.  Arterioscler Thromb Vasc Biol. 2003;23(6):1042-1047. PubMedGoogle ScholarCrossref
9.
Buchwald  H, Avidor  Y, Braunwald  E,  et al.  Bariatric surgery: a systematic review and meta-analysis.  JAMA. 2004;292(14):1724-1737. PubMedGoogle ScholarCrossref
10.
Torquati  A, Lutfi  R, Abumrad  N, Richards  WO.  Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients?  J Gastrointest Surg. 2005;9(8):1112-1118. PubMedGoogle ScholarCrossref
11.
Cossu  ML, Noya  G, Tonolo  GC,  et al.  Duodenal switch without gastric resection: results and observations after 6 years.  Obes Surg. 2004;14(10):1354-1359. PubMedGoogle ScholarCrossref
12.
Rubino  F, Gagner  M, Gentileschi  P,  et al.  The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism.  Ann Surg. 2004;240(2):236-242. PubMedGoogle ScholarCrossref
13.
Pories  WJ, Swanson  MS, MacDonald  KG,  et al.  Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus.  Ann Surg. 1995;222(3):339-352. PubMedGoogle ScholarCrossref
14.
Dixon  JB, O’Brien  PE, Playfair  J,  et al.  Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial.  JAMA. 2008;299(3):316-323. PubMedGoogle ScholarCrossref
15.
MacDonald  KG  Jr, Long  SD, Swanson  MS,  et al.  The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus.  J Gastrointest Surg. 1997;1(3):213-220. PubMedGoogle ScholarCrossref
16.
Pories  WJ, MacDonald  KG  Jr, Morgan  EJ,  et al.  Surgical treatment of obesity and its effect on diabetes: 10-y follow-up.  Am J Clin Nutr. 1992;55(2)(suppl):582S-585S. PubMedGoogle Scholar
17.
le Roux  CW, Aylwin  SJ, Batterham  RL,  et al.  Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.  Ann Surg. 2006;243(1):108-114. PubMedGoogle ScholarCrossref
18.
Parikh  M, Ayoung-Chee  P, Romanos  E,  et al.  Comparison of rates of resolution of diabetes mellitus after gastric banding, gastric bypass, and biliopancreatic diversion.  J Am Coll Surg. 2007;205(5):631-635. PubMedGoogle ScholarCrossref
19.
Zingmond  DS, McGory  ML, Ko  CY.  Hospitalization before and after gastric bypass surgery.  JAMA. 2005;294(15):1918-1924. PubMedGoogle ScholarCrossref
20.
Haslam  DW, James  WP.  Obesity.  Lancet. 2005;366(9492):1197-1209. PubMedGoogle ScholarCrossref
21.
Hossain  P, Kawar  B, El Nahas  M.  Obesity and diabetes in the developing world—a growing challenge.  N Engl J Med. 2007;356(3):213-215. PubMedGoogle ScholarCrossref
22.
Wild  S, Roglic  G, Green  A, Sicree  R, King  H.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.  Diabetes Care. 2004;27(5):1047-1053. PubMedGoogle ScholarCrossref
23.
Fagot-Campagna  A, Pettitt  DJ, Engelgau  MM,  et al.  Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective.  J Pediatr. 2000;136(5):664-672. PubMedGoogle ScholarCrossref
24.
Brandle  M, Zhou  H, Smith  BR,  et al.  The direct medical cost of type 2 diabetes.  Diabetes Care. 2003;26(8):2300-2304. PubMedGoogle ScholarCrossref
Original Article
August 2010

Medication Utilization and Annual Health Care Costs in Patients With Type 2 Diabetes Mellitus Before and After Bariatric Surgery

Author Affiliations

Author Affiliations: Departments of Health Policy and Management (Drs Makary, Shore, Weiner, and Wu and Mr Richards) and Biostatistics (Dr Dominici), Johns Hopkins Bloomberg School of Public Health, and Departments of Surgery (Drs Makary and Magnuson) and Medicine (Drs Clark, Bass, Wu, and Segal), The Johns Hopkins University School of Medicine, Baltimore, Maryland.

Arch Surg. 2010;145(8):726-731. doi:10.1001/archsurg.2010.150
Abstract

Objective  To examine the relationship of bariatric surgery with the use of diabetes medications and with total health care costs in patients with type 2 diabetes mellitus.

Design  We studied 2235 adults with type 2 diabetes and commercial health insurance who underwent bariatric surgery in the United States during a 4-year period from January 1, 2002, through December 31, 2005. We used administrative claims data to measure the use of diabetes medications at specified time intervals before and after surgery and total median health care costs per year.

Setting  Seven states in the Blue Cross/Blue Shield Obesity Care Collaborative.

Patients  Two thousand two hundred thirty-five patients with type 2 diabetes mellitus who underwent bariatric surgery.

Results  Surgery was associated with elimination of diabetes medication therapy in 1669 of 2235 patients (74.7%) at 6 months, 1489 of 1847 (80.6%) at 1 year, and 906 of 1072 (84.5%) at 2 years after surgery. Reduction of use was observed in all classes of diabetes medications. The median cost of the surgical procedure and hospitalization was $29 959. In the 3 years following surgery, total annual health care costs per person increased by 9.7% ($616) in year 1 but then decreased by 34.2% ($2179) in year 2 and by 70.5% ($4498) in year 3 compared with a preoperative annual cost of $6376 observed from 1 to 2 years before surgery.

Conclusions  Bariatric surgery is associated with reductions in the use of medication and in overall health care costs in patients with type 2 diabetes. Health insurance should cover bariatric surgery because of its health and cost benefits.

×